



PHARMING

Extraordinary General Meeting of Shareholders

February 3, 2012

Jaap Blaak, Chairman

Sijmen de Vries, CEO

Karl Keegan, CFO

The information contained in this document and made verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published, in whole or in part, for any purpose.

The Presentation does not form any part of an offer of, or invitation to apply for, securities in Pharming Group N.V. (the "Company").

The Presentation speaks as of its date. The Company assumes no obligation to notify or inform the recipient of any developments or changes occurring such date of this document that might render the contents of the Presentation untrue or inaccurate in whole or in part. In addition, no representation or warranty, express or implied, is given as to the accuracy of the information or opinions contained in the Presentation and no liability is accepted for any such information or opinions by the Company or any of its directors, members, officers, employees, agents or advisers.

The Presentation contains forward-looking statements, including statements about our beliefs and expectations. These statements are based on our current plans, estimates and projections, as well as our expectations of external conditions and events. Forward-looking statements involve inherent risks and uncertainties and speak only as of the date they are made. The Company undertakes no duty to and will not necessarily update any of them in light of new information or future events, except to the extent required by applicable law.

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the Securities Act.



Content of presentation

- Introduction
- Negative Equity Position
- Financing Objectives
- The Financing Terms
- Requested Increase of Share Capital

What is negative equity?

- The equity amount changes over the year as primarily net profits/losses are attributed to the equity position
 - Negative equity is a result of historical losses incurred
 - Typical of biotech companies at this stage of development
 - In our case, is also related to the accounting treatment of our license fee income
 - €17.9 million presented as a deferred liability at the end of Q3 2011
- Under compliance with International Financial Reporting Standards, license fee income could not be recognized in full

Accounts

Income statement

- Revenues

- Less cost of revenues
- Less operating expenses

- Operating result

- Financial income/expense
- Taxes

- Net result



Impacts
amount of
equity

NO impact on the business

Situation in Q4, 2011

- How we would address the negative equity position
 - Capital structure limit on issuing equity
 - Business development potential income is not guaranteed
 - Also may be subject to deferred recognition (accounting)
- Bridge the company through to the results of Study 1310
 - Key event for the company
 - Crucial step towards US commercialisation
 - Associated with significant cash milestones
 - These milestones can be recognised, not deferred
 - Improves equity position

The Financing Terms

- Pharming receives €8 million in cash
- The bonds have a fixed conversion price of €0.12
- At the option of the Company the bonds may be redeemed in cash or shares
 - Six equal monthly tranches between February and July 2012
- Coupon of 8.5 percent per annum
- 38.7 million warrants will be issued to investors
 - Exercisable for 5 years
 - Exercise price of €0.12

Financing Outcomes

- Key Objective: Bridge the financing gap to readout of 1310
 - Post financing Pharming has cash runway into 2013
 - Includes anticipated milestones
 - Not including cash receipts from Ruconest sales
 - Not including additional partnering initiatives
 - Geographical for Ruconest/Rhucin
 - New projects (e.g rhFVIII)
- Flexibility of repayment is important
- The 12 cents strike price for the warrants is an important signal

Requested Increase of Share Capital

- Raising the authorized share capital
 - 255 million shares to 805 million shares
 - Increase calculated based on nominal value
- Allows Pharming to meet the terms of recent financing
 - Study 1310 read out is critical event
- Maintains flexibility required to raise additional funds
 - Appropriate to address negative equity position
 - Management aware of dilution concerns
 - But (still) needed to build and unlock value of the business

www.pharming.com
NYSE Euronext: PHARM